APVO Aptevo Therapeutics Inc

Price (delayed)

$5.03

Market cap

$6.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$78.78

Enterprise value

-$3.84M

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, ...

Highlights
The company's debt fell by 4.5% QoQ
APVO's EPS has dropped by 102% year-on-year but it is up by 10% since the previous quarter
Aptevo Therapeutics's equity has decreased by 33% QoQ
The quick ratio has contracted by 15% from the previous quarter

Key stats

What are the main financial stats of APVO

APVO stock price

How has the Aptevo Therapeutics stock price performed over time
Intraday
0.2%
1 week
0.6%
1 month
-7.71%
1 year
-94.37%
YTD
-46.66%
QTD
17.8%

Financial performance

How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.67M
Net income
-$26.26M
Gross margin
N/A
Net margin
N/A
APVO's net income is down by 11% YoY
The company's operating income fell by 11% YoY

Price vs fundamentals

How does APVO's price correlate with its fundamentals

Growth

What is Aptevo Therapeutics's growth rate over time

Valuation

What is Aptevo Therapeutics stock price valuation
P/E
N/A
P/B
0.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APVO's EPS has dropped by 102% year-on-year but it is up by 10% since the previous quarter
APVO's P/B is 84% below its 5-year quarterly average of 3.1 but 28% above its last 4 quarters average of 0.4
Aptevo Therapeutics's equity has decreased by 33% QoQ

Efficiency

How efficient is Aptevo Therapeutics business performance
The return on equity has surged by 73% year-on-year and by 24% since the previous quarter
The company's return on invested capital fell by 40% YoY and by 2.1% QoQ
Aptevo Therapeutics's ROA has increased by 29% YoY and by 12% from the previous quarter

Dividends

What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APVO.

Financial health

How did Aptevo Therapeutics financials performed over time
APVO's total assets is 140% higher than its total liabilities
APVO's total assets has soared by 139% YoY but it is down by 27% QoQ
The total liabilities has contracted by 16% YoY and by 16% from the previous quarter
The company's debt is 62% lower than its equity
The debt to equity has soared by 113% YoY and by 41% QoQ
Aptevo Therapeutics's equity has decreased by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.